drugset / Trial / NCT02251132

Pharmacokinetics of Tipranavir Soft Elastic Capsules (SEDDS) and Ritonavir and Their Effects on Cytochrome P-450 (3A4) in Healthy Volunteers

NCT02251132

Phase 1 Completed 113 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to establish the tipranavir-ritonavir steady-state dose-exposure relationships when administered on a b.i.d. dosing regimen; to determine the effects of tipranavir (TPV) and ritonavir (RTV) on cytochrome P-450 (CYP3A4) activity; to establish the dependency of the TPV M1 metabolite on RTV co-administration. Additionally, the short-term safety and tolerance of this drug combination will be evaluated.

Timeline

Start
2000-10
Primary completion
2000-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ritonavir Other / unclassified
Subject Tipranavir Small molecule
Background Erythromycin Small molecule

Indications

No indication recorded.